CURA THERAPEUTICS INC.

Cura Therapeutics is a biotech company developing a first-in-class multifunctional immunotherapy platform to treat a wide range of solid malignancies, infectious diseases, and other undisclosed applications. Cura's immunotherapies harness cytokines and immune receptors to create multifunctional proteins with novel immunomodulatory properties. Cura Therapeutics has developed a revolutionary immunotherapy platform designed to treat a wide range of solid malignancies. Cura's lead immunotherapy CT101 is a multifunctional cytokine fusion protein that activates and synchronizes major immune system mechanisms to destroy cancer cells. The company's immunotherapy's ability to reactivate the immune system's response against cancer while disrupting the tumour's blood supply sets them apart. Currently, no treatments on the market combine these major anti-cancer properties in one drug. The company is actively seeking strategic partnering opportunities and collaborations with pharmaceutical and biotechnology companies to develop and commercialize cancer immunotherapies based on their multifunctional fusion proteins.